The Immuno-oncology Drugs Market is estimated to be valued at US$ 1020.24 Bn in 2023 and is expected to exhibit a CAGR of 16.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immuno-oncology drugs are specialized biologics that work by stimulating the body's natural defenses to fight cancer. These drugs help boost the ability of ... Read more
PARP inhibitors are emerging as an important therapeutic class of drugs for the treatment of various cancers like ovarian cancer, breast cancer, and prostate cancer. PARP inhibitors act by inhibiting the DNA repair enzyme called Poly (ADP-ribose) polymerase. The inhibition of PARP enzyme prevents cancer cells from repairing DNA damage caused by chemotherapy or radiation therapy. This leads to cell death in cancer cells. PARP inhibitors are increasingly being used as a maintenance therapy for ... Read more
Cancer remains one of the leading causes of death worldwide. While traditional treatment methods like chemotherapy, radiation therapy and surgery have improved clinical outcomes for many cancer patients, new approaches are still needed to make cancer a manageable disease. Oncolytic virus therapy is an emerging and promising new strategy that harnesses viruses to selectively target and kill cancer cells.
Cancer has affected millions of people worldwide and remains one of the leading causes of death. For decades, the standard treatments for cancer included surgery, chemotherapy, and radiation therapy. While these therapies have helped many patients, there remains significant room for improvement. In recent years, immunotherapy has emerged as a revolutionary new approach that is transforming how we treat cancer. Immunotherapy, also called biologic therapy, aims to boost the body's natural ... Read more
